The present invention relates to a platelet additive solution (PAS) having an amount of one or more β-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents and one or more of PAS components that include a salt, a citrate source, a carbon source, or any combination thereof.